伴同性诊断市场规模、份额和成长分析：按产品/服务、技术、适应症和地区 - 产业预测，2024-2031 年

2022年全球伴同性诊断市场规模将为66.2亿美元，从2023年的73.7亿美元增长到2031年的174.8亿美元，并且预计在预测期内（2024-2031年）将以复合年增长率增长。年为11.4%。

伴同性诊断对于安全有效地使用某些生物製药和药物至关重要，特别是在癌症的诊断和治疗中。这些测试对于透过识别特定的生物标记为个别患者量身定制治疗策略至关重要。例如，Foundation Medicine 的 FOUNDATIONONE CDx 是一种出色的伴同性诊断，可对 300 多个癌症相关基因进行全面分析。这种详细的基因分析提供了重要的见解，将有助于指导针对各种固体癌的标靶治疗和个人化癌症治疗的选择。伴同性诊断使医疗保健专业人员能够做出明智的治疗方法，从而显着提高根据患者个体需求量身定制的癌症治疗的有效性和安全性。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价格分析
• 价值链分析
• 供应链分析
• 贸易分析
• 市场生态系统
• Start-Ups分析
• 专利分析
• 客户和购买标准分析
• 监管环境
• 创新矩阵
• 重点投资分析
• 关键成功因素
• 市场魅力指数
• 竞争程度

伴同性诊断市场：依产品/服务分类

• 市场概况
• 测定、套件和试剂
• 设备和系统
• 软体服务

伴同性诊断市场：依技术分类

• 市场概况
• 聚合酵素链锁反应
• 原位杂交
• 次世代定序
• 免疫组织化学
• 其他技术

伴同性诊断市场：依适应症分类

• 市场概况
• 癌症
  • 肺癌
  • 乳癌
  • 血癌
  • 大肠直肠癌
  • 其他癌症
• 神经系统疾病
• 心血管疾病
• 感染疾病
• 其他适应症

伴同性诊断市场：依样本类型

• 市场概况
• 组织样本
• 血液样本
• 其他样品类型

伴同性诊断市场：依最终用户分类

• 市场概况
• 製药和生物技术公司
• 参考实验室
• 医疗保健/製药
• 其他最终用户

伴同性诊断市场规模：按地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• IDEXX Laboratories, Inc.（US）
• Zoetis Inc.（US）
• Heska Corporation（US）
• Thermo Fisher Scientific, Inc.（US）
• Virbac SA（France）
• IDVet（France）
• NEOGEN Corporation（US）
• bioMerieux SA（France）
• Randox Laboratories Ltd.（UK）
• AniCell Biotech（US）
• Bionote Inc.（South Korea）
• Bio-Rad Laboratories, Inc.（US）
• Antech Diagnostics（US）
• Eurofins Scientific SE（Luxembourg）
• Animalytix LLC（US）
• Advanced Animal Diagnostics（US）
• Roche Diagnostics（Switzerland）
• Agilent Technologies, Inc.（US）
• Myriad Genetics, Inc.（US）
• Illumina, Inc.（US）
• Qiagen NV（Netherlands）

Global Companion Diagnostic Market size was valued at USD 6.62 billion in 2022 and is poised to grow from USD 7.37 billion in 2023 to USD 17.48 billion by 2031, growing at a CAGR of 11.4% in the forecast period (2024-2031).

Companion diagnostics are essential for the safe and effective use of specific biological products or medications, especially in cancer diagnosis and treatment. These tests are pivotal in customizing therapeutic strategies for individual patients by identifying particular biomarkers. For instance, Foundation Medicine's FOUNDATIONONE CDx is a notable companion diagnostic that offers a thorough analysis of over 300 cancer-related genes. This detailed genetic analysis provides critical insights that help in selecting targeted and personalized cancer treatments for a wide range of solid tumors. By enabling healthcare professionals to make well-informed decisions about treatment options, companion diagnostics significantly improve both the efficacy and safety of cancer therapies tailored to individual patient needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Companion Diagnostic market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Companion Diagnostic Market Segmental Analysis

The Companion Diagnostic Market is segmented based on product and services, Technology, indication and region. Based on product and services, the market is segmented into assay kits and reagents, and software and services. Based on industry, the market is segmented into polymerase chain reaction, immunohistochemistry, in situ hybridization, and next-generation sequencing, among others. Based on indication, the market is segmented into oncology, neurology, and others. Based on region, the market is segmented into North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

Drivers of the Global Companion Diagnostic Market

Recent years have seen a significant rise in cancer cases, leading to increased demand for effective Companion Diagnostic (CDx) assays. This growing prevalence highlights the importance of genomic testing, which provides a detailed understanding of tumors' genetic profiles. Genomic testing helps characterize the genetic makeup of tumors and offers precise guidance to healthcare professionals on appropriate treatment strategies. Consequently, the rise in cancer cases is driving up sales of CDx products. These diagnostics are crucial for personalizing treatment approaches, ensuring that patients receive targeted therapies based on their tumors' specific genetic features, and ultimately improving the effectiveness of cancer care.

Restraints in the Global Companion Diagnostic Market

Despite the increasing acceptance of companion diagnostic tests, a significant challenge remains due to the lack of a standardized method for setting reimbursement rates. Currently, these rates are determined on a case-by-case basis, leading to inconsistencies in the reimbursement process. For instance, our analysis reveals that in Germany, there is a notable variance in reimbursement structures between inpatient and outpatient care settings. In the inpatient system, diagnostics are generally covered under diagnosis-related groups, which provides a standardized approach within this context.

Market Trends of the Global Companion Diagnostic Market

Clinicians use Next-Generation Sequencing (NGS) to analyze a broad array of genes related to cancer development, utilizing surgically excised tumor samples from patients. NGS is distinguished by its ability to produce extensive genetic data quickly, making it a crucial tool in oncology. Ongoing technological advancements continue to improve the accuracy and effectiveness of this sequencing technique. According to a publication by the Centers for Disease Control and Prevention (CDC), NGS has evolved from being primarily a research tool to becoming a central element in clinical applications over the past five years. This transition highlights NGS's growing importance in understanding the genetic complexities of cancers, which enhances the precision and effectiveness of diagnostic and treatment strategies in clinical practice.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Trade Analysis
• Ecosystem of the Market
• Start-up Analysis
• Patent Analysis
• Customer & Buying Criteria Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Companion Diagnostic Market by Product & Service

• Market Overview
• Assays, Kits, and Reagents
• Instruments & Systems
• Software & Services

Companion Diagnostic Market by Technology

• Market Overview
• Polymerase Chain Reaction
• In Situ Hybridization
• Next-Generation Sequencing
• Immunohistochemistry
• Other Technologies

Companion Diagnostic Market by Indication

• Market Overview
• Cancer
  • Lung Cancer
  • Breast Cancer
  • Blood Cancer
  • Colorectal Cancer
  • Other Cancer
• Neurological Diseases
• Cardiovascular Diseases
• Infectious Diseases
• Other Indications

Companion Diagnostic Market by sample Types

• Market Overview
• Tissue Samples
• Blood Samples
• Other Sample types

Companion Diagnostic Market by End-User

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Reference Laboratories
• Healthcare and Pharmaceutical
• Other End Users

Companion Diagnostic Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• IDEXX Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zoetis Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heska Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDVet (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NEOGEN Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AniCell Biotech (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bionote Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Antech Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific SE (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Animalytix LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Animal Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments